ROBOSENSE
27.12.2021 17:06:12 CET | Business Wire | Press release
RoboSense , a world's leading smart LiDAR system technology company, attended the 2021 BYD CEO annual meeting of investor enterprises and officially announced a strategic investment agreement and a strategic cooperation framework agreement with BYD. Chunxin Qiu, founder and CEO of RoboSense, and Chuanfu Wang, chairman and president of BYD attended the signing ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211227005067/en/
RoboSense is a pioneer in the core technologies of LiDAR hardware, smart sensor software and chips. As the partnership deepens, RoboSense will keep pace with BYD, continuously upgrade the technological capacity in intelligent perception, and form a deeply integrated technology matrix to broaden the vertical coverage across the industry chain and jointly promote the innovation and transformation of the smart new energy vehicle industry.
The in-depth partnership with RoboSense is a strategic milestone for BYD, highlighting its focus on intelligence solutions and comprehensive planning on the intelligent vehicle industry chain.
Themed “Focus on Innovation, Co-build Ecology and Shape the Future”, the 2021 BYD CEO annual meeting invited over 20 enterprises to showcase their technological product innovations. Several LiDAR products of RoboSense were showcased, among which the second generation smart solid-state LiDAR RS-LiDAR-M1 (“M1”) became a spotlight.
A roundtable forum themed “Industrial Transformation and Domestic Production Opportunities in the Trend Toward Vehicle Intelligence” was held in parallel with the annual meeting. Chunchao Qiu, co-founder and executive president of RoboSense, attended the forum and discussed the future trends of the global automotive industry and he said: “The global auto industry is trending towards intelligence, LiDAR is a core part of vehicle intelligence, and the industry market performance shows resource concentration on top performers. RoboSense secured fixed-point project orders of multiple models in 2021, gaining a competitive edge.”
BYD's investment will help RoboSense engage more closely in the smart new energy vehicle industry ecology, laying a solid foundation for in-depth industry collaboration between the two companies. The partnership between RoboSense and BYD will unlock greater potential in smart new energy vehicles, and explore the smart LiDAR technology in a practical and innovation-driven manner, and mobilize industry resources to promote the sustainable development of the global intelligent vehicle industry ecology.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
ABOUT BYD
The Official Sponsor of Mother Nature™, BYD, the world’s leading electric vehicle company, is dedicated to creating a “total solution.” Globally, BYD has committed to corporate social responsibility, deeply monitoring our supply chain in terms of human rights, environmental safety, hazardous substance control and intellectual property rights. We only select suppliers who share our commitment to just labor practices, human rights standards and the environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211227005067/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom